Many oncologists do not order molecular testing for precision oncology treatment despite the established benefits. An article in JCO Precision Oncology examined the rationales behind these decisions. Around 78% said that they were unpersuaded of the relevance or clinical utility, and another 72% relied on testing individual genes.
According to Pro Pharma’s Pharmacy Benefit News, “Modern oncology has been given crucial testing markers to target therapy. The use of these markers is critical for patients and their clinical outcomes. The findings of the above study indicate that specialists in evaluating multi-marker gene panels are a crucial addition to all centers of treatment!”
Register for Pharmacy Benefits News to get this story and more by clicking here.
(Source: Pharmacy Benefits News, December 9th, 2021)